Welcome to Beacon Equity Research. Today is Sunday, 20 January 2008
 Home   Covered Companies   News and Commentary   TraderNotes   Our Team   Ratings   Contact Us   Charity   Affiliates  
   

Archive >> January 2007

Recently, the EU approved "Orphan Drug Status" for Xechem International's sickle cell drug dubbed Niprisan, a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease.

Immune Response Corporation recently announced on that it has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax, an investigational T-cell receptor peptide vaccine for the treatment of MS. Immune went on further to announce that in November they will hold a clinical trial meeting in Budapest, Hungary to discuss plans for a multi-center trial. This trial will also be a double-blind placebo control test to further investigate the viability of NeuroVax as a treatment for MS.

Axial Vector Engine Corp recently announced that it was closing its private placement after receiving $2.7M from its investors at $2.00 per share. Dr. Raymond Brouzes, President and CEO of Axial Vector stated, "We are extremely pleased by the support of our shareholders who provided this very favorable financing to the company.

22 Jan, 2007

Covered Companies




 
Copyright 2007 Beacon Equity Research